ASX Announcements

Neuren receives $1 million R&D Tax Incentive
Investor presentation, 3 April 2017
Full Year Statutory Accounts
Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome
Trading Halt
S&P DJ Indices Announces March Quarterly Rebalance
Preliminary Final Report
Investor presentation, 2 February 2017
Appendix 4C - quarterly
Neuren completes Phase 2 trial in pediatric Rett syndrome